OTCMKTS:EDTXF Spectral Diagnostics Q3 2025 Earnings Results & Report $0.73 -0.01 (-1.35%) As of 11/13/2026 10:03 AM Eastern Spectral Diagnostics missed analyst expectations on both earnings and revenue in its Q3 2025 results, released November 7, 2025. The company reported EPS of -$0.08 versus the -$0.0072 consensus estimate, while revenue of $485 thousand fell short of the $541 thousand estimate by $56.00 thousand. Research:ProfileEarnings History Earnings Announcement Details QuarterQ3 2025Report DateNovember 7, 2025TimeBefore Market Opens Spectral Diagnostics EPS ResultsActual EPS-$0.08Consensus EPS -$0.0072Beat/MissMissed by -$0.0728One Year Ago EPSN/AEPS Beat Rate0 of last 4 quartersSpectral Diagnostics Revenue ResultsActual Revenue$485 thousandExpected Revenue$541 thousandBeat/MissMissed by -$56.00 thousandYoY Revenue GrowthN/AConference Call ResourcesEarnings HistoryCompany Profile Spectral Diagnostics Q3 2025 Earnings FAQ Did Spectral Diagnostics beat earnings estimates for Q3 2025? Spectral Diagnostics (OTCMKTS:EDTXF) reported earnings of -$0.08 per share for Q3 2025, missing the consensus estimate of -$0.0072. The report was announced on Friday, November 7, 2025. What was Spectral Diagnostics' revenue for Q3 2025? Spectral Diagnostics reported revenue of $485 thousand for Q3 2025, against a consensus estimate of $541 thousand. Spectral Diagnostics Earnings HeadlinesSpectral Medical Inc EDTXFSeptember 23, 2026 | morningstar.comMSpectral Medical Announces U.S. FDA Filing of PMA Application for PMXJune 25, 2026 | globenewswire.comI'm handing you this one freeElon Musk doesn't own the chip powering every Tesla, every Starlink dish, and every AI satellite he builds. He licenses it from one overlooked company. That supplier just got a major catalyst. Musk filed to launch 1,000,000 satellites, a move analyst Dylan believes could drive a 100X bigger bill for this chipmaker starting December 8th.November 14 at 1:00 AM | Behind the Markets (Ad)Spectral Medical Inc. Announces Results of Annual and Special Meeting of ShareholdersJune 9, 2026 | globenewswire.comSpectral Medical and Vantive Announce Topline 12 Month Follow-Up Results From Spectral's Tigris TrialJune 4, 2026 | globenewswire.comSpectral Medical Announces PMA Submission to U.S. FDA for PMXMay 29, 2026 | globenewswire.comSee More Spectral Diagnostics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Spectral Diagnostics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Spectral Diagnostics and other key companies, straight to your email. Email Address About Spectral DiagnosticsSpectral Diagnostics, now known as Spectral Medical Inc., is a Toronto-based medical technology company focused on the diagnosis and treatment of sepsis and septic shock. Its work centers on detecting endotoxin, a bacterial toxin associated with severe infection and organ dysfunction. The company’s Endotoxin Activity Assay (EAA) is a blood test designed to help clinicians identify elevated endotoxin activity in critically ill patients. Spectral also develops polymyxin B hemoperfusion, an extracorporeal therapy intended to remove endotoxin from the blood; the therapy has been studied for use in patients with septic shock. Formerly named Spectral Diagnostics (OTCMKTS:EDTXF), the company has focused on sepsis-related products for decades. Its activities include developing and commercializing the EAA and advancing its endotoxin-removal therapy through clinical research.View Spectral Diagnostics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles 3 Building-Materials Stocks Rallying While Homebuilders Struggle to Find BuyersMarketBeat Week in Review – 11/9 - 11/13Nu Holdings Earnings Show a Compounder Priced Like a Brazil BetCerebras Q3 Results: How Much More Proof Does Wall Street Need?YETI Beat on Earnings, But Its Sales Tell a Different StoryCostco's Record $30 Dividend Shows Just How Strong Its Cash Machine IsLightPath Technologies' Record Backlog Highlights a Bigger Defense Opportunity Upcoming Earnings Home Depot (11/17/2026)Walt Disney (11/17/2026)NVIDIA (11/17/2026)Lowe's Companies (11/18/2026)TJX Companies (11/18/2026)Target (11/18/2026)Palo Alto Networks (11/18/2026)NetEase (11/19/2026)Alibaba Group (11/19/2026)PDD (11/19/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
